Compare NEON & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | MIRA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 33.7M |
| IPO Year | 2007 | 2023 |
| Metric | NEON | MIRA |
|---|---|---|
| Price | $1.90 | $1.49 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 212.9K | ★ 226.9K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $2,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $0.73 |
| 52 Week High | $29.90 | $2.45 |
| Indicator | NEON | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 50.10 |
| Support Level | $1.85 | $1.45 |
| Resistance Level | $1.96 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 46.97 | 33.33 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.